2. Academic Validation
  3. Novel Isoindolinone-Containing PARP Inhibitors: Synthesis and Therapeutic Applications in CNS Cancer Treatment

Novel Isoindolinone-Containing PARP Inhibitors: Synthesis and Therapeutic Applications in CNS Cancer Treatment

  • ACS Med Chem Lett. 2025 Jul 24;16(8):1497-1498. doi: 10.1021/acsmedchemlett.5c00410.
Xin Zhou 1,  Steven H Liang 1
Affiliations

Affiliation

  • 1 Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, Georgia 30322, United States.
PMID: 40832517 DOI: 10.1021/acsmedchemlett.5c00410
Abstract

This patent discloses the development and therapeutic applications of novel poly-(ADP-ribose) polymerase (PARP) inhibitors featuring an isoindolinone scaffold. These isoindolinone-based PARP inhibitors represent a strategically designed class of central nerve system (CNS) Cancer therapeutics that combine potent PARP inhibitory activity with enhanced blood-brain barrier (BBB) permeability.

Figures
Products